Findd.AI | $21,000,000 | (May 22, 2026)
CVRD Health | $5,000,000 | (May 22, 2026)
checker | $8,000,000 | (May 22, 2026)
Imperagen
United Kingdom
- Manchester, England
- 22/05/2026
- Seed
- $5,000,000
Imperagen is advancing enzyme engineering through an integrated, AI-driven platform that enables faster and more precise development of high-performance enzymes. By combining advanced computational modeling with automated lab testing, we help companies improve production processes while reducing cost, time, and environmental impact.
Founded by researchers from the Manchester Institute of Biotechnology, Imperagen brings together expertise in physics-based simulation, machine learning, and high-throughput experimentation. Our closed-loop platform continuously learns from real-world data, allowing us to design, test, and refine enzymes with greater accuracy and efficiency than traditional approaches .
We take a problem-specific approach, tailoring each solution to the unique requirements of a given enzyme, reaction, and application. We work with organizations across pharma, life sciences, chemicals, food, and consumer goods to solve complex enzyme engineering challenges. Our approach helps reduce development risk, shorten timelines, and support the shift toward more sustainable, enzyme-based manufacturing.
Get in touch to learn more about our innovative platform and discover how we can quickly transform your enzyme needs into market-ready solutions.
- Industry Biotechnology Research
- Website https://imperagen.com/
- LinkedIn https://www.linkedin.com/company/imperagen/
Related People
Guy Levy-YuristaFounder
United States -
Washington DC-Baltimore Area
Scaling deep tech companies from bold ideas to multi-million-dollar customer contracts and investor returns.
♦ STARTUP; SCALE-UP LEADER – 3.9x ARR growth and 7.5x TCV expansion at Synthace, securing multi-year enterprise deals with Pfizer, AstraZeneca, GSK, Sanofi, and AbbVie.
♦ P&L AND TEAM LEADERSHIP – Led global SaaS and deep tech companies through scale-up and market adoption, managing cross-functional teams in the US, UK, and EU.
♦ COMMERCIAL TURNAROUND – Doubled active pipeline and landed the largest contracts in company history at Synthace, shifting the business to enterprise-grade recurring revenue.
♦ NEW MARKET ENTRY – Led go-to-market pivots for AI-driven platforms in life sciences and big data analytics, including the launch of Sisense BIVE to introduce AI into Analytics.
♦ FUNDRAISING; INVESTOR RELATIONS – Secured multi-million-dollar VC, and institutional funding across multiple ventures; managed Boards and investor communications.
♦ M&A; STRATEGIC PARTNERSHIPS – Spearheaded strategic partnerships with leading pharma, biotechs, and research institutions; advised on M&A opportunities in the AI, event ticket pricing and digital health sectors.
♦ GLOBAL IMPACT – Israeli-American leader with a global footprint, scaling businesses in Europe, the US, and Asia; fluent in navigating cross-border markets and investor ecosystems.
Oorja Bio | $30,000,000 | (May 22, 2026)
Neurosoft Bioelectronics | $7,500,000 | (May 22, 2026)
Hark(1) | $700,000,000 | (May 22, 2026)
LawX | $8,709,375 | (May 22, 2026)